Process Mass Intensity (PMI): A Holistic Analysis of Current Peptide Manufacturing Processes Informs Sustainability in Peptide Synthesis

Ivy Kekessie,Katarzyna Wegner,Isamir Martinez,Michael E. Kopach,Timothy D. White,Janine K. Tom,Martin N. Kenworthy,Fabrice Gallou,John Lopez,Stefan G. Koenig, Philippa R. Payne, Stefan Eissler, Balasubramanian Arumugam,Changfeng Li, Subha Mukherjee,Albert Isidro-Llobet, Olivier Ludemann-Hombourger,Paul Richardson, Jorg Kittelmann,Daniel Sejer Pedersen, Leendert J. van den Bos

JOURNAL OF ORGANIC CHEMISTRY(2024)

引用 0|浏览5
暂无评分
摘要
Small molecule therapeutics represent the majority of the FDA-approved drugs. Yet, many attractive targets are poorly tractable by small molecules, generating a need for new therapeutic modalities. Due to their biocompatibility profile and structural versatility, peptide-based therapeutics are a possible solution. Additionally, in the past two decades, advances in peptide design, delivery, formulation, and devices have occurred, making therapeutic peptides an attractive modality. However, peptide manufacturing is often limited to solid-phase peptide synthesis (SPPS), liquid phase peptide synthesis (LPPS), and to a lesser extent hybrid SPPS/LPPS, with SPPS emerging as a predominant platform technology for peptide synthesis. SPPS involves the use of excess solvents and reagents which negatively impact the environment, thus highlighting the need for newer technologies to reduce the environmental footprint. Herein, fourteen American Chemical Society Green Chemistry Institute Pharmaceutical Roundtable (ACS GCIPR) member companies with peptide-based therapeutics in their portfolio have compiled Process Mass Intensity (PMI) metrics to help inform the sustainability efforts in peptide synthesis. This includes PMI assessment on 40 synthetic peptide processes at various development stages in pharma, classified according to the development phase. This is the most comprehensive assessment of synthetic peptide environmental metrics to date. The synthetic peptide manufacturing process was divided into stages (synthesis, purification, isolation) to determine their respective PMI. On average, solid-phase peptide synthesis (SPPS) (PMI approximate to 13,000) does not compare favorably with other modalities such as small molecules (PMI median 168-308) and biopharmaceuticals (PMI approximate to 8300). Thus, the high PMI for peptide synthesis warrants more environmentally friendly processes in peptide manufacturing.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要